Theriva Biologics, Inc. (TOVX)

NYSEAMERICAN: TOVX · IEX Real-Time Price · USD
0.670
-0.030 (-4.29%)
Dec 6, 2022 3:31 PM EST - Market open
-4.29%
Market Cap 11.09M
Revenue (ttm) n/a
Net Income (ttm) -19.70M
Shares Out 15.84M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 70,248
Open 0.715
Previous Close 0.7
Day's Range 0.67 - 0.715
52-Week Range 0.575 - 4.39
Beta 1.28
Analysts Buy
Price Target 5.61 (+737.3%)
Earnings Date Nov 10, 2022

About TOVX

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and... [Read more]

Industry Biotechnology
IPO Date Jun 26, 2006
CEO Steven Shallcross
Employees 16
Stock Exchange NYSEAMERICAN
Ticker Symbol TOVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TOVX stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 737.31% from the latest price.

Price Target
$5.61
(737.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Theriva Biologics to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat ca...

5 days ago - GlobeNewsWire

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

–Reported encouraging clinical data supporting the differentiated mode-of action of Theriva's novel oncolytic adenovirus (OV) platform–

3 weeks ago - GlobeNewsWire

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and ...

-Conference call to be held on Friday, November 11 at 8:30 a.m. ET-

3 weeks ago - GlobeNewsWire

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financ...

ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat ca...

1 month ago - GlobeNewsWire

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase...

- Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee -

1 month ago - GlobeNewsWire

Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus The...

-Webinar to feature presentation from immunotherapy experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D., on Monday, November 7th at 11 a.m. ET- -Webinar to feature presentation from immunotherapy ...

1 month ago - GlobeNewsWire

Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing...

- Data to be featured in an oral presentation highlighting the encouraging biological activity of VCN-01 treatment in combination with durvalumab- - Data to be featured in an oral presentation highlight...

1 month ago - GlobeNewsWire

Synthetic Biologics Rebrands as Theriva Biologics

Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration Rebrand solidifies sharpened clinical development strategy to...

Other symbols: SYN
1 month ago - GlobeNewsWire